Method for Surgical Closing of Muscle Biopsy Sites on Nonhuman Primates in Group Housing
Using Anti-Drug-Antibody Screening Assay to Resolve Selectivity Issues in Toxicokinetic Ligand-Binding Assay
Mitigation of On-Column Conversion of Ivabradine to Desmethylivabradine Metal Chelation With Citric Acid Modifier
Dual Purpose of a Cell-Based Assay for an Agonist of the GLP-2 Receptor
Development of an Oligonucleotide Drug Immunogenicity Assay: A Case for the Characterization of the Immune Response
Moving Your Drug Forward to Preclinical Trials
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Your drug discovery phase is nearing completion and your funding is in place. What comes next?
Five Ways Altasciences Simplifies the Drug Development Process for You
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Bringing new drugs to market, from lead candidate selection through preclinical testing, to clinical proof of concept, is a complex, time-consuming, and costly process.